{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010493","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.852187+00:00","generated_at":"2026-06-11T18:12:57.478698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M","bullets":["Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).","Net loss $5.3M ($0.005/sh) unchanged YoY; adjusted non-GAAP EBITDA loss $3.1M.","Cash & equivalents $142.4M, down from $186.8M YoY; normalized operating burn ~$3M.","Gross margin 67%; adjusted >70% excluding one-time costs; consumable revenue $4.0M (+48% YoY).","Due diligence on potential SMP (VetGuardian) acquisition progressing; TRUVIEW digital microscopy launched late June."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010493","json":"https://secwatch.observer/filing/0001654954-23-010493.json","markdown":"https://secwatch.observer/filing/0001654954-23-010493.md","text":"https://secwatch.observer/filing/0001654954-23-010493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/0001654954-23-010493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:12:57.478698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35abdf651c25e8df56fb079113d499d428602f10","claim":"Zomedica Corp. reported the quarter ended June 30, 2023 results: revenue $6.0 million.","evidence_excerpt":"or incorporated by reference therein. --- EX-99.1 (EX-99.1) --- zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) (\"Zomedica\" or the \"Company\"), a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/0001654954-23-010493-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$6.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}